221 related articles for article (PubMed ID: 23643785)
1. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
Culig Z; Santer FR
Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor signaling in prostate cancer.
Culig Z; Santer FR
Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
4. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado B; Marin Aguilera M; Pereira MV
Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
[TBL] [Abstract][Full Text] [Related]
5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Kim W; Jones JO; Diamond M; Haqq C; Molina A; Small EJ; Ryan CJ
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):292-9. PubMed ID: 25047002
[TBL] [Abstract][Full Text] [Related]
7. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
8. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Bryce A; Ryan CJ
Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs.
Kumar S; Jaiswal B; Kumar S; Negi S; Tyagi RK
Biochem Pharmacol; 2010 Oct; 80(7):964-76. PubMed ID: 20599793
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
11. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
12. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer.
Fletterick RJ
BJU Int; 2005 Dec; 96 Suppl 2():2-9. PubMed ID: 16359432
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
Culig Z; Steiner H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]